Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
NVGN's Cash to Debt is ranked higher than
98% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.22 vs. NVGN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NVGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.92  Med: N/A Max: No Debt
Current: No Debt
Equity to Asset 0.97
NVGN's Equity to Asset is ranked higher than
99% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NVGN: 0.97 )
Ranked among companies with meaningful Equity to Asset only.
NVGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.72 Max: 0.97
Current: 0.97
0.32
0.97
F-Score: 4
Z-Score: 13.55
M-Score: -3.81
WACC vs ROIC
12.45%
-979.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -5383.27
NVGN's Operating margin (%) is ranked lower than
98% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. NVGN: -5383.27 )
Ranked among companies with meaningful Operating margin (%) only.
NVGN' s Operating margin (%) Range Over the Past 10 Years
Min: -10886.52  Med: -203.93 Max: -105.2
Current: -5383.27
-10886.52
-105.2
Net-margin (%) -3476.49
NVGN's Net-margin (%) is ranked lower than
98% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.01 vs. NVGN: -3476.49 )
Ranked among companies with meaningful Net-margin (%) only.
NVGN' s Net-margin (%) Range Over the Past 10 Years
Min: -8583.91  Med: -161.18 Max: 90.46
Current: -3476.49
-8583.91
90.46
ROE (%) -27.80
NVGN's ROE (%) is ranked lower than
82% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.85 vs. NVGN: -27.80 )
Ranked among companies with meaningful ROE (%) only.
NVGN' s ROE (%) Range Over the Past 10 Years
Min: -269.02  Med: -52.48 Max: 33.98
Current: -27.8
-269.02
33.98
ROA (%) -26.46
NVGN's ROA (%) is ranked lower than
84% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. NVGN: -26.46 )
Ranked among companies with meaningful ROA (%) only.
NVGN' s ROA (%) Range Over the Past 10 Years
Min: -143.49  Med: -39.8 Max: 12.06
Current: -26.46
-143.49
12.06
ROC (Joel Greenblatt) (%) -970.40
NVGN's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 773 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.35 vs. NVGN: -970.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -14620.2  Med: -1650.53 Max: -196.47
Current: -970.4
-14620.2
-196.47
Revenue Growth (3Y)(%) -100.00
NVGN's Revenue Growth (3Y)(%) is ranked lower than
99% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. NVGN: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -18.45 Max: 5.3
Current: -100
-100
5.3
EBITDA Growth (3Y)(%) 26.00
NVGN's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. NVGN: 26.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -78.5  Med: -10.45 Max: 33.9
Current: 26
-78.5
33.9
EPS Growth (3Y)(%) 28.90
NVGN's EPS Growth (3Y)(%) is ranked higher than
80% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.40 vs. NVGN: 28.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -57.8  Med: -10.35 Max: 28.9
Current: 28.9
-57.8
28.9
» NVGN's 10-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

NVGN Guru Trades in Q3 2015

Jim Simons 167,800 sh (-22.17%)
» More
Q4 2015

NVGN Guru Trades in Q4 2015

Jim Simons 139,100 sh (-17.10%)
» More
Q1 2016

NVGN Guru Trades in Q1 2016

Jim Simons 137,300 sh (-1.29%)
» More
Q2 2016

NVGN Guru Trades in Q2 2016

Jim Simons 137,300 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NVGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NAS:PRPH, OTCPK:CHEXF, AMEX:AXN, OTCPK:INNV, OTCPK:SUWN, NAS:ALQA, NAS:IMNP, NAS:TNXP, AMEX:CPHI, OTCPK:ECTE, NAS:BSPM, OTCPK:INBP, OTCPK:CKDXY, OTCPK:ENZB, OTCPK:ADIA, OTCPK:PXSLY, NAS:ALIM, OTCPK:FAMDF, OTCPK:BIOYF, AMEX:NNVC » details
Traded in other countries:NRT.Australia, NV9B.Germany, NVGNF.USA,
Novogen Ltd is a pharmaceutical drug development based on a simple benzopyran chemical structure.

Novogen Ltd. was incorporated in March 1994 under the jurisdiction of the laws of New South Wales, Australia. The Company is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose. The Company's inaugural drug candidate CS-6 belongs to a new class of drug candidates known as Mitochondrial Electron Transfer Inhibitors that work by depriving the cancer cell of its main energy source. The Company's competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions. The activities of the Company are subject to numerous Australian laws and regulations.

Ratios

vs
industry
vs
history
P/B 1.03
NVGN's P/B is ranked higher than
84% of the 696 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. NVGN: 1.03 )
Ranked among companies with meaningful P/B only.
NVGN' s P/B Range Over the Past 10 Years
Min: 0.92  Med: 4.15 Max: 45.56
Current: 1.03
0.92
45.56
EV-to-EBIT -0.68
NVGN's EV-to-EBIT is ranked lower than
99.99% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.25 vs. NVGN: -0.68 )
Ranked among companies with meaningful EV-to-EBIT only.
NVGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.9  Med: -2.8 Max: 0.4
Current: -0.68
-19.9
0.4
EV-to-EBITDA -0.74
NVGN's EV-to-EBITDA is ranked lower than
99.99% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.16 vs. NVGN: -0.74 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.3  Med: -3 Max: 0.4
Current: -0.74
-26.3
0.4
Current Ratio 27.14
NVGN's Current Ratio is ranked higher than
98% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. NVGN: 27.14 )
Ranked among companies with meaningful Current Ratio only.
NVGN' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 6.12 Max: 27.14
Current: 27.14
0.81
27.14
Quick Ratio 27.14
NVGN's Quick Ratio is ranked higher than
99% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. NVGN: 27.14 )
Ranked among companies with meaningful Quick Ratio only.
NVGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 5.48 Max: 27.14
Current: 27.14
0.81
27.14
Days Sales Outstanding 363.55
NVGN's Days Sales Outstanding is ranked lower than
99% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.99 vs. NVGN: 363.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.51  Med: 56.21 Max: 435.3
Current: 363.55
1.51
435.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -59.30
NVGN's 3-Year Average Share Buyback Ratio is ranked lower than
94% of the 430 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. NVGN: -59.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -59.3  Med: -1.8 Max: -0.2
Current: -59.3
-59.3
-0.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.25
NVGN's Price/Net Cash is ranked higher than
95% of the 201 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.98 vs. NVGN: 1.25 )
Ranked among companies with meaningful Price/Net Cash only.
NVGN' s Price/Net Cash Range Over the Past 10 Years
Min: 1.43  Med: 4.92 Max: 23.09
Current: 1.25
1.43
23.09
Price/Net Current Asset Value 1.11
NVGN's Price/Net Current Asset Value is ranked higher than
95% of the 439 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.53 vs. NVGN: 1.11 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVGN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.25  Med: 3.75 Max: 19
Current: 1.11
1.25
19
Price/Tangible Book 1.06
NVGN's Price/Tangible Book is ranked higher than
85% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.74 vs. NVGN: 1.06 )
Ranked among companies with meaningful Price/Tangible Book only.
NVGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.28  Med: 3.66 Max: 160
Current: 1.06
1.28
160
Earnings Yield (Greenblatt) (%) -147.10
NVGN's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. NVGN: -147.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -283.01  Med: 0 Max: 0
Current: -147.1
-283.01
0

More Statistics

Revenue (TTM) (Mil) $0.19
EPS (TTM) $ -0.49
Beta0.96
Short Percentage of Float0.05%
52-Week Range $1.72 - 3.09
Shares Outstanding (Mil)17.16

Analyst Estimate

Jun16 Jun17 Jun18
Revenue (Mil $) 2 4 3
EPS ($) -0.55 -0.56 -0.74
EPS w/o NRI ($) -0.55 -0.56 -0.74
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NVGN

Headlines

Articles On GuruFocus.com
Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and NeoPhotonic Mar 04 2015 

More From Other Websites
Conversion of Convertible Notes Sep 13 2016
Novogen secures key US drug study approval Sep 12 2016
US FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in... Sep 11 2016
Resignation/appointment of Company Secretary Sep 11 2016
FDA approves IND application for Cantrixil Sep 11 2016
Novogen Announces FDA Approves IND Application for Cantrixil in Ovarian Cancer Sep 11 2016
Novogen appoints Scientific Advisory Board to guide development of oncology pipeline Sep 04 2016
Appendix 4E and Full Year Statutory Accounts Aug 30 2016
Novogen appoints Key Management Personnel to drive transition to a development-focused organisation Aug 28 2016
Novogen Submits IND Application to the US FDA for Cantrixil in Ovarian Cancer Aug 14 2016
Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in... Aug 11 2016
Novogen Patent Covering Anisina(TM) Has Proceeded to Grant Jun 13 2016
Novogen Patent Covering Anisina Has Proceeded to Grant Jun 13 2016
Edison Investment Research Report maintains valuation as Novogen resumes 100% ownership of Cantrixil May 09 2016
Novogen Provides Update On Development Of Cantrixil May 01 2016
Novogen Provides Update on Development of Cantrixil May 01 2016
Cantrixil (TRXE-002-1) Abstract (AACR Annual Meeting 2016) Apr 17 2016
Novogen Receives R&D Tax Incentive Cash Refund Mar 16 2016
Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant Feb 19 2016
Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed Feb 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)